Drug Profile
Research programme: anti-hepatitis C antibodies - Integrated BioTherapeutics/Stanford University
Alternative Names: Hepatitis C antibodies - Integrated BioTherapeutics/Stanford UniversityLatest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator Integrated BioTherapeutics; Stanford University
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Hepatitis C in USA (unspecified route)
- 28 Jul 2020 No recent reports of development identified for preclinical development in Hepatitis-C in USA
- 29 Jun 2016 Preclinical trials in Hepatitis C in USA (unspecified route) before June 2016